Bicalutamide is a non-steroidal antiandrogen, lacking other endocrine activity. It binds to androgen receptors without activating gene expression and thus inhibits androgen stimulation, causing inhibition of prostate tumor regression. WIBICAL® is available in two different strengths (50 mg and 150 mg) and in blister packs of 30 capsules. WIBICAL® (50mg) is mainly indicated for the treatment of advanced prostate cancer in combination with hormonal therapy (LHRH agonists) or surgical castration. WIBICAL® (150mg) is indicated, either alone or as an adjunct to radical prostatectomy or radiotherapy, in patients with locally advanced prostate cancer at high risk of disease progression.
For further information: